Source: Eur Respir J 2010; 36: 202-204
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kiakouama L., Cottin V., Etienne-mastroianni B., Khouatra C., Humbert M., Cordier J.F.. Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. Eur Respir J 2010; 36: 202-204

Member's Comments

No comment yet.

Related content which might interest you: Clinical study of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Pulmonary hypertension in pulmonary Langerhans’ cell histiocytosis Source: Eur Respir Mon 2012; 57: 161-165 Year: 2012 Pathological findings in histiocytosis X with pulmonary hypertension Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012 RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite) Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension Source: Eur Respir J, 50 (4) 1700465; 10.1183/13993003.00465-2017 Year: 2017 Chronic thrombo-embolic pulmonary hypertension: Long-term outcomes in operated and non-operated patients Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Pulmonary hypertension in orphan lung diseases Source: Eur Respir Mon 2011; 54: 317-331 Year: 2011 Pulmonary hypertension in patients with chronic myeloproliferative disorders Source: Eur Respir J 2010; 35: 1396-1406 Year: 2010 Pulmonary hypertension associated with sarcoidosis Source: Eur Respir Mon 2012; 57: 166-181 Year: 2012 IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment Source: Eur Respir J 2014; 43: 1516-1519 Year: 2014 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009